Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Abstract

In organ-transplant recipients, the standard two-dose vaccination strategy for coronavirus disease 2019 (Covid-19) has suboptimal immunogenicity.¹ Both patients and health care providers have questioned whether a third-dose booster in transplant recipients would be safe and enhance immune response.² We performed a double-blind, randomized, controlled trial of a third dose of mRNA-1273 vaccine (Moderna) as compared with placebo (the protocol is available with the full text of this letter at NEJM.org; ClinicalTrials.gov number, NCT04885907).